The U.S. FDA has ordered new warning labels on GLP-1 drugs to indicate a rare risk of a condition that can cause vision loss.

What it means

The U.S. Food and Drug Administration (FDA) has ordered that all GLP-1 receptor agonist drugs (such as Ozempic, Wegovy, and Mounjaro) carry a new warning about a rare but serious eye condition called non-arteritic anterior ischemic optic neuropathy (NAION), which can cause sudden, permanent vision loss. This class-wide labeling change follows a safety review that found a potential increased risk of NAION with these medications.

Accuracy & sourcesGrounded

The claim is solid, based directly on the FDA's own safety communication issued on November 9, 2026. Multiple reputable news outlets (NBC News, The Washington Post, BBC, The Guardian) are reporting the same details, and the FDA's official announcement is publicly available. The reporting sits very close to the primary source.

How new

Genuinely new: the FDA announced the warning on November 9, 2026, and news outlets covered it on November 9–10, 2026.

Go deeper